Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration

International Journal of Cancer

Volumn 75, Issue 2, 1998, Pages 233-238

  Hagenaars, Martin ^a   Geeske Ensink, N ^a   Koelemij, Ron ^a   Basse, Per H ^b   Eggermont, Alexander M M ^c   Van de Velde, Cornelis J H ^a   Fleuren, Gert Jan ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; HEPATIC ARTERY; JUGULAR VEIN; LIVER METASTASIS; MALE; NATURAL KILLER CELL; NONHUMAN; PERITONEAL CAVITY; PORTAL VEIN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; RATS; RATS, WISTAR;

EID: 2642648679     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980119)75:2<233::AID-IJC11>3.0.CO;2-E     Document Type: Article

References (25)

1. BASSE, P.H., HERBERMAN, R.B., HOKLAND, M.E. and GOLDFARB, R.H., Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration. Nat. Immun., 11, 193-202 (1992a).
2. BASSE, P.H., HERBERMAN, R.B., NANNMARK, U., JOHANSSON, B.R., HOKLAND, M., WASSERMAN, K. and GOLDFARB, R.H., Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. exp. Med., 174, 479-488 (1991a).
3. BASSE, P.H., HOKLAND, P., GUNDERSEN, H.J.G. and HOKLAND, M., Enumeration of organ-associated natural killer cells in mice: application of a new stereological method. Acta pathol. microbiol. immunol. Scand., 100, 202-208 (1992b).
4. BASSE, P.H., NANNMARK, U., JOHANSSON, B.R., HERBERMAN, R.B. and GOLDFARB, R.H., Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J. nat. Cancer Inst., 83, 944-950 (1991b).
5. ESHHAR, Z. and GROSS, G., Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. Brit. J. Cancer, 62(Suppl. 10), 27-29 (1990).
6. FELGAR, R.E. and HISERODT, J.C., In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell. Immunol., 129, 288-298 (1990).
7. FERLAZZO, G., SCISCA, C., IEMMO, R., CAVALIERE, R., QUARTARONE, G., ADAMO, V., FRAZZETTO, G., COSTA, G. and MELIOLI, G., Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. J. Immunother., 20, 158-163 (1997).
8. GIEZEMAN-SMITS, K.M., KUPPEN, P.J.K., ENSINK, N.G., EGGERMONT, A.M.M., STALS, F., WONIGETT, K. and FLEUREN, G.J., The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells. Immunobiology, 195, 286-299 (1996).
9. KEILHOLZ, U., SCHEIBENBOGEN, C., BRADO, M., GEORGI, P., MACLACHLAN, D., BRADO, B. and HUNSTEIN, W., Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Europ. J. Cancer, 30A, 103-105 (1994).
10. KUPPEN, P.J.K., BASSE, P.H., GOLDFARB, R.H., VAN DE VELDE, C.J.H., FLEUREN, G.J. and EGGERMONT, A.M.M., The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats. Int. J. Cancer, 56, 574-579 (1994).
11. KUPPEN, P.J.K., MARINELLI, A., CAMPS, J.A.J., PAUWELS, E.K.J., VAN DE VELDE, C.J.H., FLEUREN, G.J. and EGGERMONT, A.M.M., Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion. Int. J. Cancer, 52, 266-270 (1992).
12. LAFRENIERE, R. and ROSENBERG, S.A., Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res., 45, 3735-3741 (1985a).
13. LAFRENIERE, R. and ROSENBERG, S.A., Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J. Immunol., 135, 4273-4280 (1985b).
14. MAGHAZACHI, A.A., GOLDFARB, R.H. and HERBERMAN, R.B., Effect of carbohydrates on the in vivo migration of purified LAK cells. In: E.W. Ades and C. Lopez, (eds.), Natural killer cells and host defence, pp. 242-245. Karger, Basel (1989).
15. MARQUET, R.L., WESTBROEK, D.L. and JEEKEL, J., Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int. J. Cancer, 33, 689-692 (1984).
16. MULÉ, J.J., YANG, J., SHU, S. and ROSENBERG, S.A., The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J. Immunol., 136, 3899-3909 (1986).
17. NANNMARK, U., BASSE, P., JOHANSSON, B.R., KUPPEN, P., KJAERGAARD, J. and HOKLAND, M., Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumor-bearing animals. Nat. Immun., 15, 78-86 (1996).
18. OKADA, K., NANNMARK, U., VUJANOVIC, N.L., WATKINS, S., BASSE, P., HERBERMAN, R.B. and WHITESIDE, T.L., Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive. Cancer Res., 56, 1599-1608 (1996).
19. RABINOWICH, H., VITOLO, D., ALTARAC, S., HERBERMAN, R.B. and WHITESIDE, T.L., Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. J. Immunol., 149, 340-349 (1992).
20. RATTO, G.B., ZINO, P., MIRABELLI, S., MINUTI, P., AQUILINA, R., FANTINO, G., SPESSA, E., PONTE, M., BRUZZI, P. and MELIOLI, G., A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer, 78, 244-251 (1996).
21. SASAKI, A., MELDER, R.J., WHITESIDE, T.L., HERBERMAN, R.B. and JAIN, R.K., Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J. nat. Cancer Inst., 83, 433-437 (1991).
22. SCHWARZ, R.E., VUJANOVIC, N.L. and HISERODT, J.C., Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res., 49, 1441-1446 (1989).
23. VUJANOVIC, N.L., HERBERMAN, R.B., MAGHAZACHI, A.A. and HISERODT, J.C., Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J. exp. Med., 167, 15-29 (1988).
24. WANG, L.-Q., PERSSON, B.C., BERGQVIST, L. and BENGMARK, S., Influence of dearterialization on distribution of absolute tumor blood flow between hepatic artery and portal vein. Cancer, 74, 2454-2459 (1994).
25. ZHIJ, H., MELDER, R.J., BAXTER, L.T. and JAIN, R.K., Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res., 56, 3771-3781 (1996).